Oxford Nanopore Technologies (ONT) 44th Annual J.P. Morgan Healthcare Conference summary

Strategic vision and platform evolution

• Developed a transformative multi-omics platform enabling analysis of DNA, RNA, and expanding into proteomics and metabolite measurement, aiming for analysis of any biological sample by anyone, anywhere.

• Platform validated by over 20,000 publications, a decade of innovation, and a global footprint in more than 125 countries.

• Reads native DNA and RNA directly, allowing detection of modifications, real-time data streaming, and supporting multi-omic analysis.

• Ongoing innovation includes adaptive sampling, peptide measurement, direct RNA sequencing, and early-stage proteomics.

• New product launches and device updates, such as GridION Dx and MinION MK1D, enhance robustness, throughput, and ease of use.

Financial performance and growth

• Five-year CAGR of 28%, with FY25 revenues estimated at GBP 223–224 million, reflecting 24% constant currency growth.

• Over 70% of revenues from sequencing consumables; cash and equivalents exceed GBP 300 million at year-end 2025.

• Revenue growth exceeded 20% in all regions, with clinical segment growing 60%, biopharma 30%, and applied industrial 27%.

• Shifted to a CAPEX model for large devices, improving cash flow and gross margin structurally.

• Targeting EBITDA break-even by 2027, with over 62% gross margin and ongoing cost restructurings.

Market expansion and applications

• Life science research tools remain core, but applied markets now represent a third of revenues.

• Key markets include research, applied industrial, clinical, and biopharma, each showing double-digit YoY growth.

• Clinical applications include rapid infectious disease diagnostics, oncology, rare disease detection, and carrier screening.

• Biopharma partnerships enable faster RNA characterization, real-time viral contamination testing, and QC workflows validated in GMP environments.

• Large-scale population genomics projects, such as PRECISE and UK Biobank, and NHS metagenomics scaling, drive innovation and revenue.